CAV1 and prostate cancer: Patients with low stromal Cav-1 and high stromal PDGFR beta (seen only in 7% of the patients in this material) was found to have an approximately 3-fold excess risk of prostate cancer death compared to the other patient groups suggesting that a combination of these two types of stroma has a synergistic effect on tumor aggressiveness.